Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Campbell Soup Co. (CPB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Campbell Soup Co. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Campbell Soup Co. trades at $22.15 (market cap $6.58B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.1× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays a 7.07% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CPB | |
|---|---|---|
Market Cap | $39.89B | $6.58B |
Sector | Health | Consumer Staples |
52-Week High | $491.22 | $34.03 |
52-Week Low | $278.09 | $20.00 |
Enterprise Value | $38.15B | $13.19B |
Dividend Yield | — | 7.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Campbell's (CPB) trades at $22.07, up 2.79% today, with a bearish technical signal and mixed earnings history. The stock shows attractive valuation metrics with a P/E of 10.82 and P/S of 0.67, but profitability remains modest with a 6.12% net margin. Recent news highlights cost-cutting efforts and a 7% dividend yield, though sales declines and margin pressures persist.
Outlook is cautious due to weak analyst consensus (only 3.45% buy ratings) and structural margin challenges. The stock offers value and income potential but faces headwinds from inflation and competitive pressures. Risks include execution on cost savings and consumer demand volatility, with the consensus price target at $20.00 suggesting limited upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
